Calithera Biosciences Company Profile (NASDAQ:CALA)

About Calithera Biosciences (NASDAQ:CALA)

Calithera Biosciences logoCalithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. The Company's lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, is being developed for hematology and oncology indications. CB-1158 is a potent and selective orally bioavailable inhibitor of the enzyme arginase. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. CB-1158 has single agent anti-tumor activity in syngeneic mouse tumor models that has been demonstrated to act through an immune mechanism. CB-1158 is being tested in a Phase I clinical trial in patients with solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CALA
  • CUSIP: N/A
  • Web: www.calithera.com
Capitalization:
  • Market Cap: $615.51 million
  • Outstanding Shares: 35,476,000
Average Prices:
  • 50 Day Moving Avg: $16.15
  • 200 Day Moving Avg: $14.69
  • 52 Week Range: $2.20 - $20.05
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.52
  • P/E Growth: -0.29
Sales & Book Value:
  • Annual Revenue: $11.45 million
  • Price / Sales: 53.76
  • Book Value: $4.58 per share
  • Price / Book: 3.79
Profitability:
  • EBITDA: ($29,120,000.00)
  • Return on Equity: -26.72%
  • Return on Assets: -20.91%
Debt:
  • Current Ratio: 4.95%
  • Quick Ratio: 4.95%
Misc:
  • Average Volume: 510,203 shs.
  • Beta: 3.27
  • Short Ratio: 3.93
 

Frequently Asked Questions for Calithera Biosciences (NASDAQ:CALA)

What is Calithera Biosciences' stock symbol?

Calithera Biosciences trades on the NASDAQ under the ticker symbol "CALA."

How were Calithera Biosciences' earnings last quarter?

Calithera Biosciences, Inc. (NASDAQ:CALA) announced its earnings results on Tuesday, August, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.14. The company earned $7.26 million during the quarter, compared to analyst estimates of $4.80 million. View Calithera Biosciences' Earnings History.

When will Calithera Biosciences make its next earnings announcement?

Calithera Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Calithera Biosciences.

Where is Calithera Biosciences' stock going? Where will Calithera Biosciences' stock price be in 2017?

6 brokers have issued 12-month price objectives for Calithera Biosciences' shares. Their predictions range from $5.00 to $20.00. On average, they expect Calithera Biosciences' share price to reach $14.40 in the next twelve months. View Analyst Ratings for Calithera Biosciences.

What are analysts saying about Calithera Biosciences stock?

Here are some recent quotes from research analysts about Calithera Biosciences stock:

  • 1. According to Zacks Investment Research, "Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. " (7/13/2017)
  • 2. JMP Securities analysts commented, "Calithera Biosciences reports achievement of PK and PD goals in the Phase I trial of CB-1158, which entitles the company to receive a $12MM milestone payment as per its collaboration agreement with Incyte (INCY, MO, PT UR, Bayko); reiterate our Market Outperform rating and $12 price target based on a synthesis of our DCF, SOTP, and comparable company valuation methodologies. We view this early milestone achievement as further validation of the company's collaboration with INCY as well as of the subject of the agreement, CB-1158, a first-in-class arginase inhibitor and potential immunotherapeutic. CB-1158 has thus far demonstrated favorable pharmacologic activity in human subjects, with elevated plasma arginine levels consistent with those seen in preclinical cancer models. We remind investors that additional clinical data for CB-1158 in the setting of immuno-oncology are expected in mid-2017." (3/28/2017)

Who are some of Calithera Biosciences' key competitors?

Who are Calithera Biosciences' key executives?

Calithera Biosciences' management team includes the folowing people:

  • Susan M. Molineaux Ph.D., President, Chief Executive Officer, Co-Founder, Director
  • Curtis C. Hecht, Senior Vice President - Business and Corporate Development
  • Christopher J. Molineaux Ph.D., Senior Vice President - Development
  • Keith Orford M.D. Ph.D., Senior Vice President, Clinical Development
  • Eric B. Sjogren Ph.D., Senior Vice President - Drug Discovery
  • Stephanie Wong, Vice President - Finance, Secretary
  • Francesco Parlati Ph.D., Vice President - Research
  • Deepa R. Pakianathan Ph.D., Lead Independent Director
  • Sunil Agarwal M.D., Independent Director
  • Jonathan G. Drachman M.D., Independent Director

How do I buy Calithera Biosciences stock?

Shares of Calithera Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Calithera Biosciences' stock price today?

One share of Calithera Biosciences stock can currently be purchased for approximately $17.35.


MarketBeat Community Rating for Calithera Biosciences (NASDAQ CALA)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  202
MarketBeat's community ratings are surveys of what our community members think about Calithera Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Calithera Biosciences (NASDAQ:CALA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $14.40 (17.00% downside)
Consensus Price Target History for Calithera Biosciences (NASDAQ:CALA)
Price Target History for Calithera Biosciences (NASDAQ:CALA)
Analysts' Ratings History for Calithera Biosciences (NASDAQ:CALA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/5/2017William BlairInitiated CoverageOutperform -> OutperformN/AView Rating Details
6/12/2017HC WainwrightReiterated RatingBuy$14.00 -> $19.00LowView Rating Details
6/6/2017Wells Fargo & CompanyReiterated RatingOutperform$15.00 -> $20.00HighView Rating Details
4/3/2017Leerink SwannReiterated RatingOutperform -> Outperform$16.00MediumView Rating Details
3/28/2017JMP SecuritiesReiterated RatingOutperform$12.00 -> $12.00MediumView Rating Details
1/24/2017Citigroup Inc.UpgradeSell -> Neutral$5.00N/AView Rating Details
3/9/2016J P Morgan Chase & CoLower Price TargetMarket Outperform$20.00 -> $12.00N/AView Rating Details
(Data available from 10/16/2015 forward)

Earnings

Earnings History for Calithera Biosciences (NASDAQ:CALA)
Earnings by Quarter for Calithera Biosciences (NASDAQ:CALA)
Earnings History by Quarter for Calithera Biosciences (NASDAQ CALA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/7/2017($0.23)N/AView Earnings Details
8/8/2017Q2 2017($0.29)($0.15)$4.80 million$7.26 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.36)($0.22)$1.40 million$4.19 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.48)($0.45)ViewN/AView Earnings Details
11/9/2016Q3 2016($0.47)($0.44)ViewListenView Earnings Details
8/9/2016Q2($0.52)($0.55)ViewListenView Earnings Details
5/10/2016Q1($0.47)($0.52)ViewListenView Earnings Details
3/15/2016Q415($0.56)($0.44)ViewListenView Earnings Details
11/9/2015Q3($0.52)($0.49)ViewListenView Earnings Details
8/10/2015Q215($0.45)($0.44)ViewListenView Earnings Details
11/14/2014Q3 2014($0.28)($16.85)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Calithera Biosciences (NASDAQ:CALA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.17)($0.17)($0.17)
Q3 20172($0.27)($0.17)($0.22)
Q4 20172($0.30)($0.19)($0.25)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Calithera Biosciences (NASDAQ:CALA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Calithera Biosciences (NASDAQ:CALA)
Insider Ownership Percentage: 16.30%
Institutional Ownership Percentage: 71.88%
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)
Insider Trades by Quarter for Calithera Biosciences (NASDAQ:CALA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/28/2017Adage Capital Partners Gp, L.LMajor ShareholderSell576,000$15.64$9,008,640.00View SEC Filing  
7/17/2017Keith OrfordVPSell2,120$18.31$38,817.20View SEC Filing  
7/6/2017Curtis HechtSVPSell700$18.00$12,600.00View SEC Filing  
5/19/2017Curtis HechtSVPSell650$16.00$10,400.00View SEC Filing  
3/22/2017Adage Capital Partners Gp, L.LMajor ShareholderBuy487,804$10.25$4,999,991.00View SEC Filing  
3/13/2017Curtis HechtSVPSell600$14.00$8,400.00View SEC Filing  
11/16/2016Adage Capital Partners Gp, L.LMajor ShareholderBuy500,000$3.15$1,575,000.00View SEC Filing  
11/16/2015Curtis HechtVPSell970$6.58$6,382.60View SEC Filing  
9/23/2015Adage Capital Partners Gp LlcMajor ShareholderBuy106,968$6.03$645,017.04View SEC Filing  
9/4/2015Adage Capital Partners Gp LlcMajor ShareholderBuy90,300$5.93$535,479.00View SEC Filing  
8/28/2015Adage Capital Partners Gp LlcMajor ShareholderBuy172,126$5.27$907,104.02View SEC Filing  
10/15/2014Adage Capital Partners Gp LlcMajor ShareholderBuy181,700$6.96$1,264,632.00View SEC Filing  
10/7/2014Jean GeorgeDirectorBuy300,000$10.00$3,000,000.00View SEC Filing  
10/7/2014Morgenthaler Venture PartnersMajor ShareholderBuy350,000$10.00$3,500,000.00View SEC Filing  
10/1/2014Adage Capital Partners Gp LlcMajor ShareholderBuy800,000$10.00$8,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Calithera Biosciences (NASDAQ:CALA)
Latest Headlines for Calithera Biosciences (NASDAQ:CALA)
Source:
DateHeadline
nasdaq.com logoSurging Earnings Estimates Signal Good News for Calithera Biosciences (CALA) - Nasdaq
www.nasdaq.com - October 13 at 10:31 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - October 11 at 10:32 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Expected to Post Q3 2017 Earnings of ($0.17) Per Share
www.americanbankingnews.com - October 9 at 2:34 AM
americanbankingnews.com logoDURECT Corporation (DRRX) vs. Calithera Biosciences (CALA) Critical Survey
www.americanbankingnews.com - October 6 at 2:12 PM
americanbankingnews.com logoCalithera Biosciences Inc (CALA) Research Coverage Started at William Blair
www.americanbankingnews.com - October 5 at 5:36 PM
finance.yahoo.com logoCalithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : October 5, 2017
finance.yahoo.com - October 5 at 11:58 AM
finance.yahoo.com logoCalithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : October 4, 2017
finance.yahoo.com - October 4 at 12:35 PM
globenewswire.com logoCalithera Biosciences Announces Appointment of Sumita Ray as General Counsel - GlobeNewswire (press release)
globenewswire.com - October 3 at 4:48 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Major Shareholder Adage Capital Partners Gp, L.L Sells 576,000 Shares
www.americanbankingnews.com - September 28 at 7:24 PM
americanbankingnews.com logoContrasting Calithera Biosciences (CALA) and Ardelyx (ARDX)
www.americanbankingnews.com - September 28 at 6:24 AM
globenewswire.com logoCalithera Biosciences Appoints Blake Wise to Board of Directors - GlobeNewswire (press release)
globenewswire.com - September 22 at 3:53 PM
streetinsider.com logoCalithera Biosciences (CALA) Says CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at SITC
www.streetinsider.com - September 21 at 4:45 PM
finance.yahoo.com logoCalithera Biosciences Appoints Blake Wise to Board of Directors
finance.yahoo.com - September 21 at 4:45 PM
prnewswire.com logoStocks Under Scanner in the Biotech Space -- Aviragen Therapeutics, Blueprint Medicines, Calithera Biosciences, and ... - PR Newswire (press release)
www.prnewswire.com - September 21 at 11:19 AM
globenewswire.com logoCalithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners ... - GlobeNewswire (press release)
globenewswire.com - September 20 at 5:40 PM
finance.yahoo.com logoCalithera Biosciences to Present at the 2017 Cantor Fitzgerald Global Healthcare Conference and the Leerink Partners Immuno-Oncology Roundtable
finance.yahoo.com - September 20 at 5:40 PM
streetinsider.com logoCalithera Biosciences (CALA) Says CB-839 in Combination with ... - StreetInsider.com
www.streetinsider.com - September 19 at 9:58 PM
finance.yahoo.com logoCalithera Biosciences Announces CB-839 in Combination with Nivolumab Phase 1/2 Data Accepted for Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting
finance.yahoo.com - September 19 at 4:56 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - September 16 at 10:56 PM
finance.yahoo.com logoCalithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : September 12, 2017
finance.yahoo.com - September 12 at 5:31 PM
finance.yahoo.com logo5 Ways To Play The Biotech Bull Market
finance.yahoo.com - September 11 at 10:33 PM
nasdaq.com logoEarnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy? - Nasdaq
www.nasdaq.com - September 9 at 3:20 AM
finance.yahoo.com logoEarnings Estimates Moving Higher for Calithera Biosciences (CALA): Time to Buy?
finance.yahoo.com - September 8 at 5:15 PM
finance.yahoo.com logoHere Are 3 Strong Biotech Stocks In 2017
finance.yahoo.com - September 4 at 4:57 PM
americanbankingnews.com logoHead-To-Head Survey: Calithera Biosciences (CALA) vs. Geron Corporation (GERN)
www.americanbankingnews.com - August 31 at 2:26 PM
globenewswire.com logoCalithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare ... - GlobeNewswire (press release)
globenewswire.com - August 30 at 11:20 PM
finance.yahoo.com logoCalithera Biosciences to Participate in the Citi 12th Annual Biotech Conference and the Wells Fargo Healthcare Conference
finance.yahoo.com - August 30 at 6:17 PM
finance.yahoo.com logoCalithera Biosciences, Inc. breached its 50 day moving average in a Bullish Manner : CALA-US : August 23, 2017
finance.yahoo.com - August 23 at 5:03 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 10:44 PM
americanbankingnews.com logoContrasting Calithera Biosciences (CALA) & Cascadian Therapeutics (CASC)
www.americanbankingnews.com - August 21 at 10:22 PM
seekingalpha.com logoIDT Corporation: Revisiting The Sum-Of-The-Parts Ahead Of The Upcoming Spin-Off
seekingalpha.com - August 17 at 11:14 PM
prnewswire.com logoStock Performance Review on Biotech Industry -- Blueprint ... - PR Newswire (press release)
www.prnewswire.com - August 15 at 10:46 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Calithera Biosciences, Inc. (NASDAQ:CALA) Cut by Leerink Swann
www.americanbankingnews.com - August 11 at 9:48 AM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Posts Quarterly Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - August 9 at 10:04 PM
finance.yahoo.com logoEdited Transcript of CALA earnings conference call or presentation 8-Aug-17 8:30pm GMT
finance.yahoo.com - August 9 at 5:07 PM
finance.yahoo.com logoCalithera reports 2Q loss
finance.yahoo.com - August 8 at 9:43 PM
globenewswire.com logoCalithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
globenewswire.com - August 8 at 4:42 PM
finance.yahoo.com logoCalithera Biosciences Reports Second Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - August 8 at 4:42 PM
streetinsider.com logoCalithera Biosciences (CALA) Initiates Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell ... - StreetInsider.com
www.streetinsider.com - August 7 at 5:25 PM
finance.yahoo.com logoCalithera Biosciences Initiates a Randomized Phase 2 Combination Trial of CB-839 in Patients with Renal Cell Carcinoma
finance.yahoo.com - August 7 at 5:25 PM
finance.yahoo.com logoCalithera Biosciences, Inc. – Value Analysis (NASDAQ:CALA) : August 5, 2017
finance.yahoo.com - August 4 at 10:17 PM
globenewswire.com logoCalithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - August 2 at 10:38 PM
finance.yahoo.com logoCalithera Biosciences to Report Second Quarter 2017 Financial Results on Tuesday, August 8, 2017
finance.yahoo.com - August 2 at 5:37 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (NASDAQ:CALA) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - July 31 at 8:15 AM
americanbankingnews.com logoCalithera Biosciences, Inc. (NASDAQ:CALA) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - July 28 at 10:45 PM
finance.yahoo.com logoCalithera Biosciences, Inc. breached its 50 day moving average in a Bearish Manner : CALA-US : July 24, 2017
finance.yahoo.com - July 24 at 12:00 PM
americanbankingnews.com logoHead to Head Contrast: Calithera Biosciences (NASDAQ:CALA) versus Spring Bank Pharmaceuticals (SBPH)
www.americanbankingnews.com - July 20 at 12:40 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) VP Keith Orford Sells 2,120 Shares
www.americanbankingnews.com - July 19 at 8:00 PM
americanbankingnews.com logoCalithera Biosciences, Inc. (CALA) Short Interest Up 117.4% in June
www.americanbankingnews.com - July 15 at 7:04 AM
finance.yahoo.com logoFive Scorching Hot Stocks Screaming Higher
finance.yahoo.com - July 11 at 5:55 PM

Social

Chart

Calithera Biosciences (CALA) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.